HUE062566T2 - Heteroaromás NMDA receptor modulátorok és alkalmazásaik - Google Patents

Heteroaromás NMDA receptor modulátorok és alkalmazásaik

Info

Publication number
HUE062566T2
HUE062566T2 HUE19876025A HUE19876025A HUE062566T2 HU E062566 T2 HUE062566 T2 HU E062566T2 HU E19876025 A HUE19876025 A HU E19876025A HU E19876025 A HUE19876025 A HU E19876025A HU E062566 T2 HUE062566 T2 HU E062566T2
Authority
HU
Hungary
Prior art keywords
heteroaromatic
nmda receptor
receptor modulators
nmda
modulators
Prior art date
Application number
HUE19876025A
Other languages
English (en)
Inventor
Robert VOLKMANN
David Anderson
Sam Malekiani
Timothy PISER
Gregg Keaney
Steven Leiser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE062566T2 publication Critical patent/HUE062566T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
HUE19876025A 2018-08-03 2019-08-02 Heteroaromás NMDA receptor modulátorok és alkalmazásaik HUE062566T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03

Publications (1)

Publication Number Publication Date
HUE062566T2 true HUE062566T2 (hu) 2023-11-28

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19876025A HUE062566T2 (hu) 2018-08-03 2019-08-02 Heteroaromás NMDA receptor modulátorok és alkalmazásaik

Country Status (36)

Country Link
US (3) US10584131B2 (hu)
EP (2) EP4223760A1 (hu)
JP (1) JP7319369B2 (hu)
KR (1) KR20210039432A (hu)
CN (1) CN112513047B (hu)
AR (1) AR115905A1 (hu)
AU (1) AU2019368147A1 (hu)
BR (1) BR112021001967A2 (hu)
CA (1) CA3108519A1 (hu)
CL (1) CL2021000294A1 (hu)
CO (1) CO2021002898A2 (hu)
CR (1) CR20210125A (hu)
CU (1) CU24647B1 (hu)
CY (1) CY1126144T1 (hu)
DK (1) DK3830092T3 (hu)
DO (1) DOP2021000025A (hu)
EA (1) EA202190431A1 (hu)
EC (1) ECSP21014902A (hu)
ES (1) ES2951872T3 (hu)
FI (1) FI3830092T3 (hu)
HR (1) HRP20230774T1 (hu)
HU (1) HUE062566T2 (hu)
IL (1) IL280474B2 (hu)
JO (1) JOP20210020A1 (hu)
LT (1) LT3830092T (hu)
MA (1) MA53351B1 (hu)
MX (1) MX2021001367A (hu)
PE (1) PE20210948A1 (hu)
PH (1) PH12021550242A1 (hu)
PL (1) PL3830092T3 (hu)
PT (1) PT3830092T (hu)
RS (1) RS64359B1 (hu)
SG (1) SG11202101125VA (hu)
SI (1) SI3830092T1 (hu)
WO (1) WO2020086136A2 (hu)
ZA (1) ZA202101273B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3386591T (lt) * 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and their uses

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
AU6643694A (en) 1993-05-21 1994-12-20 Pentapharm Ag 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones
CA2257950A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
AU2001270149A1 (en) 2000-06-26 2002-01-08 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
KR100880972B1 (ko) 2004-07-13 2009-02-03 에프. 호프만-라 로슈 아게 설폰아마이드 유도체
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
JP5256202B2 (ja) 2006-09-11 2013-08-07 エム・エス・ディー・オス・ベー・フェー キナゾリノンおよびイソキノリノンアセトアミド誘導体
MX2009002685A (es) 2006-09-11 2009-10-13 Organon Nv Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).
US7858782B2 (en) 2006-12-15 2010-12-28 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
AU2008214372A1 (en) 2007-02-08 2008-08-14 Merck Sharp & Dohme Corp. Therapeutic agents
EP2160389B1 (en) 2007-04-18 2014-03-12 Probiodrug AG Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
WO2009025784A1 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
EA021938B1 (ru) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
MX2010012961A (es) 2008-05-29 2011-03-03 Sirtris Pharmaceuticals Inc Star Imidazopiridina y analogos relacionados como moduladores de sirtuina.
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作***相关受体调节剂的化合物及其应用
ES2517690T3 (es) 2008-09-29 2014-11-03 Glaxosmithkline Llc Quinazolinona, quinolona y análogos relacionados como moduladores de sirtuina
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
MX2012004289A (es) 2009-10-13 2012-06-12 Msd Oss Bv Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina.
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
CA2805724A1 (en) 2010-07-16 2012-01-19 Rockefeller University Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8946430B2 (en) 2011-09-30 2015-02-03 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
PL2776038T3 (pl) 2011-11-11 2018-06-29 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
MX354074B (es) 2012-02-10 2018-02-12 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
US9278973B2 (en) 2012-10-25 2016-03-08 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
SG11201600147TA (en) 2013-06-28 2016-02-26 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Ｎｒ２ａ之ｎ-芳基甲基磺醯胺負向調節劑
LT3055315T (lt) 2013-10-11 2018-10-25 F. Hoffmann-La Roche Ag Tiazolpirimidinonai kaip nmda receptorių aktyvumo moduliatoriai
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US20170313719A1 (en) 2014-11-18 2017-11-02 Emory University Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
EP3283487B1 (en) 2015-04-15 2019-10-16 H. Hoffnabb-La Roche Ag Pyridopyrimidinones and their use as nmda receptor modulators
KR20180102052A (ko) 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
WO2018026371A1 (en) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
KR20200088308A (ko) 2017-09-27 2020-07-22 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and their uses
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

Also Published As

Publication number Publication date
AR115905A1 (es) 2021-03-10
JP2021534227A (ja) 2021-12-09
EP3830092B1 (en) 2023-05-03
MA53351B1 (fr) 2023-08-31
AU2019368147A1 (en) 2021-03-18
PL3830092T3 (pl) 2023-11-13
HRP20230774T1 (hr) 2023-10-27
LT3830092T (lt) 2023-09-11
EA202190431A1 (ru) 2021-06-11
DOP2021000025A (es) 2021-05-31
KR20210039432A (ko) 2021-04-09
EP3830092A2 (en) 2021-06-09
CN112513047A (zh) 2021-03-16
EP4223760A1 (en) 2023-08-09
US11542264B2 (en) 2023-01-03
US20200039987A1 (en) 2020-02-06
US10584131B2 (en) 2020-03-10
WO2020086136A2 (en) 2020-04-30
US20200131190A1 (en) 2020-04-30
FI3830092T3 (fi) 2023-07-21
ECSP21014902A (es) 2021-05-31
SI3830092T1 (sl) 2023-09-29
SG11202101125VA (en) 2021-03-30
US10752633B2 (en) 2020-08-25
JOP20210020A1 (ar) 2021-01-25
JP7319369B2 (ja) 2023-08-01
MX2021001367A (es) 2021-06-23
CL2021000294A1 (es) 2021-06-18
CR20210125A (es) 2021-06-30
WO2020086136A3 (en) 2020-08-06
RS64359B1 (sr) 2023-08-31
IL280474A (en) 2021-03-01
IL280474B2 (en) 2023-09-01
DK3830092T3 (en) 2023-08-07
PT3830092T (pt) 2023-07-25
ES2951872T3 (es) 2023-10-25
PH12021550242A1 (en) 2021-11-29
CA3108519A1 (en) 2020-04-30
ZA202101273B (en) 2023-05-31
CO2021002898A2 (es) 2021-05-31
CY1126144T1 (el) 2023-11-15
BR112021001967A2 (pt) 2021-04-27
CN112513047B (zh) 2023-10-20
US20210403474A1 (en) 2021-12-30
PE20210948A1 (es) 2021-05-24
TW202019932A (zh) 2020-06-01
MA53351A (fr) 2022-01-12
CU20210013A7 (es) 2021-09-07
IL280474B1 (en) 2023-05-01
CU24647B1 (es) 2023-02-13

Similar Documents

Publication Publication Date Title
ZA201807731B (en) Spiro-lactam nmda receptor modulators and uses thereof
IL276332A (en) Spiro-lactam NMDA receptor modulators and their use
IL276330A (en) Spiro-lactam NMDA receptor modulators and their use
IL264514B (en) Spiro-lactam nmda receptor modulators and their uses
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL264397A (en) Receptor regulators of chemokines and their uses
EP3490994B8 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
DK3830092T3 (en) Heteroaromatic nmda receptor modulators and uses thereof
IL288858A (en) Transmuted heteroaromatic pyrazolopyridines and their use as glun2b receptor modulators
IL276295A (en) Modulators of chemokine receptors and their uses
EP3558318A4 (en) NMDA RECEPTOR MODULATORS AND USES THEREOF
HUE051395T2 (hu) Heteroaromás NMDA receptor modulátorok és alkalmazásaik
HK1245259A1 (zh) 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途
ZA201905511B (en) Rorgamma modulators and uses thereof
ZA201905513B (en) Rorgamma modulators and uses thereof
IL289575A (en) nmda receptor modulators